Previous 10 | Next 10 |
home / stock / nvsef / nvsef news
Fisher’s 13F portfolio value increased from $102.5B to $117.8B in Q3 2020. They increased NextEra Energy, UnitedHealth, 3M Company, and Thermo Fisher Scientific while decreasing Starbucks, Total SA, and Royal Dutch Shell during the quarter. Fisher has a number of small posi...
Kahn Brothers’ 13F portfolio value decreased from $592M to $528M this quarter. Patterson-UTI was increased while reducing Merck, Seaboard, Sterling Bancorp, and Hologic. The portfolio continues to be very concentrated with the top five positions accounting for ~48% of the 1...
Scholar Rock Holding focuses on the discovery of drugs for treating illnesses, in which signaling by protein growth factors is important. SRRK tested a total of 58 employees in Phase 2. I would expect the company to test many more patients in Phase 3. In 2019, SPINRAZA annual sale...
Olema Pharmaceuticals has filed to raise $100 million in an IPO, although the final figure may differ. The firm is advancing its OP-1250 drug to treat various women's cancers as a monotherapy and in combination with other drugs. OLMA has a collaboration deal with Novartis, which i...
Compass Therapeutics has filed to raise $50 million in an IPO. The firm is advancing programs to treat various cancers, including Her2+ breast cancer. CMPX has produced intriguing results in preclinical studies for its lead candidate. For further details see: Compass The...
Catabasis failed a Phase 3 Duchenne Muscular Dystrophy trial. Revolution Medicines reports anti-tumor activity for RMC-4630. Novartis reports positive data for iptacopan in C3 glomerulopathy. For further details see: Catabasis' Catastrophic Failure, And Other News: The G...
Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, trusts, and offshore funds. Tweedy,...
Novartis AG (NVS) Q3 2020 Earnings Conference Call October 27, 2020 9:00 am ET Company Participants Vas Narasimham - Chief Executive Officer Richard Sandor - Chief Executive Officer, Sandoz Marie-France Tschudin - President, Novartis Pharmaceuticals Susanne Schaffert - President, Novartis Onc...
The following slide deck was published by Novartis AG in conjunction with their 2020 Q3 earnings call. For further details see: Novartis AG 2020 Q3 - Results - Earnings Call Presentation
Novartis AG (NVS) Q3 2020 Earnings Conference Call October 27, 2020 08:50 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Marie-France Tschudin - President, Novartis Pharmaceuticals Susanne...
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...